A B Skotnicki

Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study

Sebastian Grosicki, Tadeusz Robak, Sławomira Kyrcz‐Krzemień et al. · Leukemia · 2004 · 126 citations · Full text

Medicine, Oncology, Pharmacology +9

Thalidomide treatment of resistant or relapsed multiple myeloma patients.

Marek Hus, Anna Dmoszyńska, Maria Soroka‐Wojtaszko et al. · PubMed · 2001 · 85 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

2‐Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7‐year experience in Poland

Tadeusz Robak, Maria Błasińska-Morawiec, J. Błasiński et al. · European Journal Of Haematology · 1999 · 82 citations

Medicine, Hematology, Oncology +8

Thymosin increases production of T-cell growth factor by normal human peripheral blood lymphocytes.

M Zatz, Janelle Oliver, Cheryl Samuels et al. · Proceedings of the National Academy of Sciences · 1984 · 62 citations · Full text

Life Sciences, Biochemistry, Immunology +12

A multicenter, open, non‐comparative, phase II study of the combination of cladribine (2‐chlorodeoxyadenosine), cytarabine, and G‐CSF as induction therapy in refractory acute myeloid leukemia – a report of the Polish Adult Leukemia Group (PALG)

Agata Wrzesień‐Kuś, Tadeusz Robak, Ewa Lech‐Marańda et al. · European Journal Of Haematology · 2003 · 61 citations

Medicine, Oncology, Pharmacology +17